Want to see FR:ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
€112.80
-€1.20(-1.06%)
At close: 4:00 PM EDT
€112.80
-€1.20(-1.06%)
Day’s Range― - ―
52-Week Range€57.50 - €139.00
Previous CloseN/A
Volume27.27K
Average Volume (3M)99.97K
Market Cap
€8.98B
Enterprise Value€6.57B
Total Cash (Recent Filing)€530.38M
Total Debt (Recent Filing)€45.89M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Sep 21, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.83
Shares Outstanding87,253,800
10 Day Avg. Volume99,142
30 Day Avg. Volume99,970
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.31
Revenue Forecast (FY)€3.81M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress Toward NDAConstructive FDA alignment reduces uncertainty around the submission package and supports progression toward a potential U.S. approval. This creates a clearer regulatory pathway for obefazimod, although commercialization still depends on successful review.
Improved Balance Sheet FlexibilityLow leverage and a larger equity base provide greater financial flexibility to fund clinical development and regulatory work. This reduces near-term balance-sheet pressure, although the company remains dependent on external capital.
Substantial New FundingThe sizeable capital raise can extend operational and development runway, helping Abivax advance obefazimod without immediate reliance on another financing. It may also strengthen negotiating leverage in potential strategic transactions.
Bears Say
No Established Commercial RevenueThe absence of recurring product revenue means the business has not yet demonstrated commercial self-sufficiency. Continued losses before potential approval leave future funding needs closely tied to clinical, regulatory, and launch execution.
Persistent Cash BurnSustained negative cash generation consumes capital while development costs continue, limiting financial resilience. Even with improved 2025 cash flow, the company remains far from self-funding and may require additional financing over time.
High Dependence On One Clinical ProgramThe investment case is concentrated around obefazimod and its ulcerative-colitis development path. Any clinical, regulatory, or manufacturing setback could materially impair future prospects because no disclosed commercial product diversifies execution risk.
Abivax SA News
ABVX FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €57.50 and its highest was €139.00 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €8.98B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Sep 21, 2026 which is in 32 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on May 22, 2026. The company reported -€0.61 earnings per share for the quarter, beating the consensus estimate of -€0.803 by €0.193.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Overvalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.84.
How many shares outstanding does Abivax SA have?
Abivax SA has 87,253,800 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€0.61 in its last earnings report, beating expectations of -€0.803. Following the earnings report the stock price went up 8.687%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in FR:ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.